The Library
A systematic review of economic evaluations assessing the cost-effectiveness of licensed drugs used for previously treated epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced/metastatic non-small cell lung cancer
Tools
Tools
Tools
Gallacher, Daniel C., Auguste, Peter, Royle, Pamela, Mistry, Hema and Armoiry, Xavier (2019) A systematic review of economic evaluations assessing the cost-effectiveness of licensed drugs used for previously treated epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced/metastatic non-small cell lung cancer. Clinical Drug Investigation, 39 . pp. 1153-1174. doi:10.1007/s40261-019-00859-5 ISSN 1173-2563.
|
PDF
WRAP-systemic-review-economic-evaluations-assessing-cost-drugs-factor-kinase-Armoiry-2019.pdf - Accepted Version - Requires a PDF viewer. Download (769Kb) | Preview |
Official URL: http://dx.doi.org/10.1007/s40261-019-00859-5
Abstract
Background
Non-small cell lung cancer (NSCLC) is one of the most commonly diagnosed cancers. There are many published studies of cost-effectiveness analyses of licensed treatments, but no study has compared these studies or their approaches simultaneously.
Objective
To investigate the methodology used in published economic analyses of licensed interventions for previously treated advanced/metastatic NSCLC in patients without anaplastic lymphoma kinase or epidermal growth factor receptor expression.
Methods
A systematic review was performed, including a systematic search of key databases (e.g. MEDLINE, EMBASE, Web of Knowledge, Cost-effectiveness Registry) limited to the period from 01 January 2001 to 26 July 2019. Two reviewers independently screened, extracted data and quality appraised identified studies. The reporting quality of the studies was assessed by using the Consolidated Health Economic Evaluation Reporting Standards and the Philips’ checklists.
Results
Thirty-one published records met the inclusion criteria, which corresponded to 30 individual cost-effectiveness analyses. Analytical approaches included partitioned survival models (n = 14), state-transition models (n = 7) and retrospective analyses of new or published data (n = 8). Model structure was generally consistent, with pre-progression, post-progression and death health states used most commonly. Other characteristics varied more widely, including the perspective of analysis, discounting, time horizon, usually to align with the country that the analysis was set in.
Conclusions
There are a wide range of approaches in the modelling of treatments for advanced NSCLC; however, the model structures are consistent. There is variation in the exploration of sensitivity analyses, with considerable uncertainty remaining in most evaluations. Improved reporting is necessary to ensure transparency in future analyses.
| Item Type: | Journal Article | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine | ||||||||
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School | ||||||||
| Library of Congress Subject Headings (LCSH): | Lungs -- Cancer -- Treatment -- Cost effectiveness, Drugs -- Cost effectiveness | ||||||||
| Journal or Publication Title: | Clinical Drug Investigation | ||||||||
| Publisher: | Adis Int. Ltd. | ||||||||
| ISSN: | 1173-2563 | ||||||||
| Official Date: | December 2019 | ||||||||
| Dates: |
|
||||||||
| Volume: | 39 | ||||||||
| Page Range: | pp. 1153-1174 | ||||||||
| DOI: | 10.1007/s40261-019-00859-5 | ||||||||
| Status: | Peer Reviewed | ||||||||
| Publication Status: | Published | ||||||||
| Access rights to Published version: | Restricted or Subscription Access | ||||||||
| Date of first compliant deposit: | 9 October 2019 | ||||||||
| Date of first compliant Open Access: | 3 October 2020 | ||||||||
| RIOXX Funder/Project Grant: |
|
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
